NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization7,777.59 mln
Float58.23 mln
Earnings Date09/21/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
149
Exceptional upside
Relative Strength
22
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-175
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
ABIVAX is a Paris-based drug development company founded in 2013, focused on creating treatments that work with the body's own immune system to manage long-term inflammatory conditions. Its most advanced medicine, obefazimod, is currently being tested in late-stage trials for ulcerative colitis and earlier-stage trials for Crohn's disease.
